Oncology and Hematology - Global Oncology Academy

1-16 of 658

Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Project Oncology®
Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Charles Turck, PharmD, BCPS, BCCCP; Daniel Geynisman, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Daniel Geynisman, MD
- Jonathan Henderson, MD
Addressing Barriers to CAR T Referral in R/R LBCL
Addressing Barriers to CAR T Referral in R/R LBCL
Project Oncology®
Addressing Barriers to CAR T Referral in R/R LBCL
Steve Jackson, PharmD; Matthew J. Matasar, MD
- Steve Jackson, PharmD
- Matthew J. Matasar, MD
- Tycel Phillips, MD
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Project Oncology®
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Steve Jackson, PharmD; Raghava Reddy Induru, MD
- Steve Jackson, PharmD
- Raghava Reddy Induru, MD
Optimizing Multidisciplinary Care in Perioperative NSCLC
Optimizing Multidisciplinary Care in Perioperative NSCLC
Project Oncology®
Optimizing Multidisciplinary Care in Perioperative NSCLC
Steve Jackson, PharmD; David Tom Cooke, MD, FACS
- Steve Jackson, PharmD
- David Tom Cooke, MD, FACS
- Joshua Reuss, MD
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Clinician's Roundtable
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Peter Buch, MD, FACG, AGAF, FACP; Aasma Shaukat, MD, MPH
- Peter Buch, MD, FACG, AGAF, FACP
- Aasma Shaukat, MD, MPH
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Project Oncology®
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Brian P. McDonough, MD, FAAFP; Bilal Siddiqui, MD
- Brian P. McDonough, MD, FAAFP
- Bilal Siddiqui, MD
Managing AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
Managing AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
Project Oncology®
Managing AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP; Neil M. Iyengar, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Neil M. Iyengar, MD
- Sarah H. Donahue, MPH, NP
Epic Aura for CRC Screening: A Real-World Perspective
Epic Aura for CRC Screening: A Real-World Perspective
Clinician's Roundtable
Epic Aura for CRC Screening: A Real-World Perspective
Natalia Usoltseva MD, FACP, MHA
- Natalia Usoltseva MD, FACP, MHA
Improving CRC Screening Conversations in Primary Care
Improving CRC Screening Conversations in Primary Care
Clinician's Roundtable
Improving CRC Screening Conversations in Primary Care
Natalia Usoltseva MD, FACP, MHA
- Natalia Usoltseva MD, FACP, MHA
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
CME/CE
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Joseph Kim, MD, MPH, MBA, FACHE; Samir Dalia, MD
0.25 credits
- Joseph Kim, MD, MPH, MBA, FACHE
- Samir Dalia, MD
- Christopher Jurief
0.25 credits
Improving CRC Screening Workflows: A PCP's Recommendations
Improving CRC Screening Workflows: A PCP's Recommendations
Clinician's Roundtable
Improving CRC Screening Workflows: A PCP's Recommendations
Natalia Usoltseva MD, FACP, MHA
- Natalia Usoltseva MD, FACP, MHA
Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Project Oncology®
Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Charles Turck, PharmD, BCPS, BCCCP; Petros Grivas, MD, PhD
- Charles Turck, PharmD, BCPS, BCCCP
- Petros Grivas, MD, PhD
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
CME/CE
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Enriqueta Felip, MD; Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
- Enriqueta Felip, MD
- Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 
Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 
MinuteCE®
Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 
Benjamin Levy, MD; Melin Khandekar, MD, PhD
1.00 program credit
- Benjamin Levy, MD
- Melin Khandekar, MD, PhD
1.00 program credit
EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions
EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions
MinuteCE®
EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions
Benjamin Levy, MD; Melin Khandekar, MD, PhD
1.00 program credit
- Benjamin Levy, MD
- Melin Khandekar, MD, PhD
1.00 program credit
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
MinuteCE®
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
Barbara O'Brien, MD; Nadia Harbeck, MD, PhD
1.00 program credit
- Barbara O'Brien, MD
- Nadia Harbeck, MD, PhD
1.00 program credit

Prev
1
2
3
…
41
42
Next

1/6